Ticker Details
Intellia Therapeutics, Inc. Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.
IPO Date:	May 6, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.63B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.09 | 3.21%
Avg Daily Range (30 D):	$0.39 | 2.96%
Avg Daily Range (90 D):	$0.42 | 3.44%

Institutional Daily Volume
Avg Daily Volume:	1.32M
Avg Daily Volume (30 D):	3.48M
Avg Daily Volume (90 D):	3.81M

Trade Size
Avg Trade Size (Sh.):	79
Avg Trade Size (Sh.) (30 D):	81
Avg Trade Size (Sh.) (90 D):	95

Institutional Trades
Total Institutional Trades:	4,948
Avg Institutional Trade:	$2.94M
Avg Institutional Trade (30 D):	$2.68M
Avg Institutional Trade (90 D):	$2.92M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$4.81M
Avg Closing Trade (30 D):	$4.32M
Avg Closing Trade (90 D):	$4.25M
Avg Closing Volume:	164.4K

News

Apr 3, 2026 @ 8:05 PM Intellia Therapeutics Reports Inducement Grants Un... Source: Intellia Therapeutics

Feb 7, 2026 @ 2:05 PM This Cathie Wood Stock Is Already Up 41% This Year... Source: Prosper Junior Bakiny

Jan 22, 2026 @ 9:56 AM Genome Editing Market Forecast to Reach $23.6 Bill... Source: Researchandmarkets.Com

Nov 4, 2025 @ 8:35 AM Gene Editing Market Size to Surpass USD 42.13 Bill... Source: Nova One Advisor

Nov 2, 2025 @ 2:25 PM Meet the Beaten-Down Biotech Stock Cathie Wood Lov... Source: Prosper Junior Bakiny

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-3.81	$-.82	$-3.81
Diluted EPS	$-3.81	$-.82	$-3.81
Revenue	$67.67M	$23.02M	$67.67M
Gross Profit
Net Income / Loss	$-412.69M	$-95.79M	$-412.69M
Operating Income / Loss	$-440.99M	$-98.71M	$-440.99M
Cost of Revenue
Net Cash Flow	$-35.22M	$-39.77M	$-35.22M
PE Ratio